Aptose Total Current Liabilities vs Net Debt Analysis

APS Stock

CAD 0.27 0.07 20.59%

Aptose Biosciences financial indicator trend analysis is way more than just evaluating Aptose Biosciences prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Aptose Biosciences is a good investment. Please check the relationship between Aptose Biosciences Total Current Liabilities and its Net Debt accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aptose Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

To learn how to invest in Aptose Stock, please use our How to Invest in Aptose Biosciences guide.

Total Current Liabilities vs Net Debt

Total Current Liabilities vs Net Debt Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Aptose Biosciences Total Current Liabilities account and Net Debt. At this time, the significance of the direction appears to have weak contrarian relationship.

The correlation between Aptose Biosciences' Total Current Liabilities and Net Debt is -0.19. Overlapping area represents the amount of variation of Total Current Liabilities that can explain the historical movement of Net Debt in the same time period over historical financial statements of Aptose Biosciences, assuming nothing else is changed. The correlation between historical values of Aptose Biosciences' Total Current Liabilities and Net Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Current Liabilities of Aptose Biosciences are associated (or correlated) with its Net Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Debt has no effect on the direction of Total Current Liabilities i.e., Aptose Biosciences' Total Current Liabilities and Net Debt go up and down completely randomly.

Correlation Coefficient

-0.19

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Total Current Liabilities

Total Current Liabilities is an item on Aptose Biosciences balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Aptose Biosciences are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Net Debt

The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.

Most indicators from Aptose Biosciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Aptose Biosciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aptose Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

To learn how to invest in Aptose Stock, please use our How to Invest in Aptose Biosciences guide.At this time, Aptose Biosciences' Selling General Administrative is very stable compared to the past year. As of the 23rd of November 2024, Sales General And Administrative To Revenue is likely to grow to 47.11, while Issuance Of Capital Stock is likely to drop about 6.5 M.

	2021	2022	2023	2024 (projected)
Net Interest Income	94K	788K	1.2M	1.2M
Interest Income	94K	779K	1.2M	577.1K

Net Interest Income Interest Income

Aptose Biosciences fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Non Currrent Assets Other	Intangible Assets	Common Stock Total Equity	Common Stock	Short Long Term Debt Total
Total Assets		0.13	0.22	0.99	0.72	-0.96	-0.36	0.31	0.96	0.58	1.0	-0.08	0.18	0.48	-0.17	-0.48	0.41	0.25	0.27	1.0	-0.3	-0.39	-0.3	0.51	0.69	-0.17
Other Current Liab	0.13		0.97	0.0	0.49	-0.1	-0.88	0.72	0.14	0.72	0.1	-0.1	0.24	-0.04	-0.2	-0.05	0.8	0.96	0.92	0.12	-0.41	-0.47	-0.36	0.89	0.65	-0.24
Total Current Liabilities	0.22	0.97		0.09	0.62	-0.19	-0.93	0.87	0.23	0.8	0.19	-0.11	0.44	-0.01	-0.18	-0.13	0.87	1.0	0.97	0.21	-0.44	-0.5	-0.39	0.92	0.74	-0.25
Total Stockholder Equity	0.99	0.0	0.09		0.64	-0.96	-0.24	0.2	0.95	0.48	0.99	-0.06	0.12	0.49	-0.15	-0.47	0.3	0.11	0.14	0.99	-0.25	-0.32	-0.25	0.39	0.6	-0.14
Property Plant And Equipment Net	0.72	0.49	0.62	0.64		-0.7	-0.63	0.74	0.71	0.89	0.7	-0.19	0.53	0.2	0.04	-0.42	0.71	0.65	0.69	0.71	-0.46	-0.64	-0.25	0.73	0.82	0.0
Net Debt	-0.96	-0.1	-0.19	-0.96	-0.7		0.33	-0.3	-1.0	-0.57	-0.96	0.08	-0.15	-0.25	0.15	0.48	-0.35	-0.22	-0.19	-0.96	0.29	0.37	0.31	-0.48	-0.64	0.16
Retained Earnings	-0.36	-0.88	-0.93	-0.24	-0.63	0.33		-0.83	-0.36	-0.74	-0.34	0.28	-0.44	-0.1	0.44	0.2	-0.9	-0.93	-0.9	-0.36	0.51	0.46	0.66	-0.97	-0.87	0.51
Accounts Payable	0.31	0.72	0.87	0.2	0.74	-0.3	-0.83		0.33	0.81	0.29	-0.1	0.8	0.0	-0.09	-0.25	0.85	0.88	0.89	0.31	-0.35	-0.49	-0.36	0.81	0.75	-0.2
Cash	0.96	0.14	0.23	0.95	0.71	-1.0	-0.36	0.33		0.6	0.96	-0.05	0.15	0.24	-0.16	-0.49	0.37	0.26	0.23	0.96	-0.31	-0.39	-0.32	0.51	0.65	-0.17
Non Current Assets Total	0.58	0.72	0.8	0.48	0.89	-0.57	-0.74	0.81	0.6		0.55	0.1	0.45	0.07	0.0	-0.39	0.7	0.82	0.83	0.57	-0.49	-0.65	-0.29	0.85	0.73	-0.05
Cash And Short Term Investments	1.0	0.1	0.19	0.99	0.7	-0.96	-0.34	0.29	0.96	0.55		-0.07	0.16	0.48	-0.16	-0.48	0.39	0.22	0.24	1.0	-0.29	-0.37	-0.29	0.48	0.68	-0.17
Net Receivables	-0.08	-0.1	-0.11	-0.06	-0.19	0.08	0.28	-0.1	-0.05	0.1	-0.07		-0.06	-0.02	0.42	-0.31	-0.32	-0.11	-0.07	-0.08	0.12	-0.15	0.43	-0.16	-0.43	0.43
Common Stock Shares Outstanding	0.18	0.24	0.44	0.12	0.53	-0.15	-0.44	0.8	0.15	0.45	0.16	-0.06		0.05	-0.01	-0.16	0.55	0.46	0.54	0.17	-0.22	-0.26	-0.18	0.37	0.47	-0.07
Short Term Investments	0.48	-0.04	-0.01	0.49	0.2	-0.25	-0.1	0.0	0.24	0.07	0.48	-0.02	0.05		-0.12	-0.26	0.21	-0.01	0.14	0.48	0.0	-0.01	-0.06	0.12	0.31	-0.17
Non Current Liabilities Total	-0.17	-0.2	-0.18	-0.15	0.04	0.15	0.44	-0.09	-0.16	0.0	-0.16	0.42	-0.01	-0.12		-0.32	-0.14	-0.17	-0.1	-0.17	0.23	-0.41	0.91	-0.31	-0.34	0.94
Other Current Assets	-0.48	-0.05	-0.13	-0.47	-0.42	0.48	0.2	-0.25	-0.49	-0.39	-0.48	-0.31	-0.16	-0.26	-0.32		-0.31	-0.15	-0.19	-0.48	0.21	0.61	-0.04	-0.32	-0.35	-0.18
Other Stockholder Equity	0.41	0.8	0.87	0.3	0.71	-0.35	-0.9	0.85	0.37	0.7	0.39	-0.32	0.55	0.21	-0.14	-0.31		0.87	0.9	0.41	-0.41	-0.61	-0.37	0.89	0.9	-0.21
Total Liab	0.25	0.96	1.0	0.11	0.65	-0.22	-0.93	0.88	0.26	0.82	0.22	-0.11	0.46	-0.01	-0.17	-0.15	0.87		0.97	0.24	-0.43	-0.51	-0.39	0.93	0.75	-0.25
Property Plant And Equipment Gross	0.27	0.92	0.97	0.14	0.69	-0.19	-0.9	0.89	0.23	0.83	0.24	-0.07	0.54	0.14	-0.1	-0.19	0.9	0.97		0.26	-0.45	-0.57	-0.32	0.9	0.76	-0.16
Total Current Assets	1.0	0.12	0.21	0.99	0.71	-0.96	-0.36	0.31	0.96	0.57	1.0	-0.08	0.17	0.48	-0.17	-0.48	0.41	0.24	0.26		-0.3	-0.38	-0.3	0.5	0.69	-0.18
Short Term Debt	-0.3	-0.41	-0.44	-0.25	-0.46	0.29	0.51	-0.35	-0.31	-0.49	-0.29	0.12	-0.22	0.0	0.23	0.21	-0.41	-0.43	-0.45	-0.3		0.43	0.41	-0.51	-0.51	0.14
Non Currrent Assets Other	-0.39	-0.47	-0.5	-0.32	-0.64	0.37	0.46	-0.49	-0.39	-0.65	-0.37	-0.15	-0.26	-0.01	-0.41	0.61	-0.61	-0.51	-0.57	-0.38	0.43		-0.11	-0.58	-0.54	-0.41
Intangible Assets	-0.3	-0.36	-0.39	-0.25	-0.25	0.31	0.66	-0.36	-0.32	-0.29	-0.29	0.43	-0.18	-0.06	0.91	-0.04	-0.37	-0.39	-0.32	-0.3	0.41	-0.11		-0.56	-0.58	0.91
Common Stock Total Equity	0.51	0.89	0.92	0.39	0.73	-0.48	-0.97	0.81	0.51	0.85	0.48	-0.16	0.37	0.12	-0.31	-0.32	0.89	0.93	0.9	0.5	-0.51	-0.58	-0.56		0.89	-0.37
Common Stock	0.69	0.65	0.74	0.6	0.82	-0.64	-0.87	0.75	0.65	0.73	0.68	-0.43	0.47	0.31	-0.34	-0.35	0.9	0.75	0.76	0.69	-0.51	-0.54	-0.58	0.89		-0.39
Short Long Term Debt Total	-0.17	-0.24	-0.25	-0.14	0.0	0.16	0.51	-0.2	-0.17	-0.05	-0.17	0.43	-0.07	-0.17	0.94	-0.18	-0.21	-0.25	-0.16	-0.18	0.14	-0.41	0.91	-0.37	-0.39

Click cells to compare fundamentals

Aptose Biosciences Account Relationship Matchups

Aptose Biosciences fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	100.5M	126.3M	82.5M	51.0M	13.0M	12.3M
Other Current Liab	3.1M	4.1M	6.0M	5.7M	11.4M	12.0M
Total Current Liabilities	5.5M	6.8M	8.2M	12.3M	15.3M	16.0M
Total Stockholder Equity	93.9M	118.9M	74.2M	37.7M	(2.9M)	(2.8M)
Property Plant And Equipment Net	1.7M	1.2M	788K	1.5M	1.1M	576.1K
Net Debt	(78.3M)	(116.3M)	(38.5M)	(35.7M)	(8.2M)	(8.6M)
Retained Earnings	(301.9M)	(357.2M)	(422.5M)	(464.3M)	(515.5M)	(489.8M)
Accounts Payable	2.0M	2.2M	1.7M	6.3M	3.5M	3.7M
Cash	79.8M	117.4M	39.1M	37.0M	9.3M	16.2M
Non Current Assets Total	1.7M	1.2M	788K	1.5M	1.1M	1.7M
Cash And Short Term Investments	97.6M	122.4M	79.1M	47.0M	9.3M	8.8M
Common Stock Shares Outstanding	3.3M	5.5M	5.9M	92.3M	6.8M	4.8M
Short Term Investments	798K	440K	17.8M	5M	40.0M	10.0M
Liabilities And Stockholders Equity	100.5M	126.3M	82.5M	51.0M	13.0M	12.3M
Non Current Liabilities Total	1.0M	535K	115K	1.0M	621K	590.0K
Other Current Assets	141K	129K	133K	257K	600K	308.0K
Other Stockholder Equity	34.6M	50.9M	63.7M	68.9M	72.1M	49.2M
Total Liab	6.6M	7.3M	8.3M	13.3M	15.9M	16.7M
Property Plant And Equipment Gross	1.7M	1.2M	3.0M	4.0M	3.9M	4.1M
Total Current Assets	98.8M	125.1M	81.7M	49.5M	11.9M	11.3M
Short Term Debt	521K	539K	459K	301K	394K	374.3K
Non Currrent Assets Other	(1.0)	(142.0)	(94.0)	(48.0)	(43.2)	(41.04)
Intangible Assets	1.0	142.0	94.0	48.0	43.2	41.04
Common Stock Total Equity	231.9M	261.1M	365.5M	429.5M	494.0M	518.6M
Common Stock	365.5M	429.5M	437.4M	437.5M	444.8M	273.5M
Net Tangible Assets	13.9M	93.8M	118.9M	74.2M	85.4M	47.6M
Property Plant Equipment	1.6M	1.1M	788K	1.5M	1.7M	1.8M
Capital Surpluse	34.6M	50.9M	63.7M	68.9M	79.2M	46.4M
Cash And Equivalents	78.2M	117.1M	38.8M	36.4M	41.8M	47.7M
Net Invested Capital	93.9M	118.9M	74.2M	37.7M	(2.9M)	(2.8M)
Net Working Capital	93.2M	118.3M	73.6M	37.2M	(3.4M)	(3.2M)
Capital Stock	365.5M	429.5M	437.4M	437.5M	444.8M	435.6M

Pair Trading with Aptose Biosciences

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Aptose Biosciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aptose Biosciences will appreciate offsetting losses from the drop in the long position's value.

Moving against Aptose Stock

0.47	WMT	Walmart Inc CDR	Pair Corr
0.36	TSLA	Tesla Inc CDR	Pair Corr
0.31	BRK	Berkshire Hathaway CDR	Pair Corr

The ability to find closely correlated positions to Aptose Biosciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Aptose Biosciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Aptose Biosciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Aptose Biosciences to buy it.

The correlation of Aptose Biosciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Aptose Biosciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Aptose Biosciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Aptose Biosciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Aptose Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Aptose Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Aptose Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Aptose Biosciences Stock:

How To Invest In Aptose

Details

Is Aptose Stock a good investment?

Details

What is Aptose Biosciences' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aptose Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

To learn how to invest in Aptose Stock, please use our How to Invest in Aptose Biosciences guide.

You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.

Please note, there is a significant difference between Aptose Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aptose Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aptose Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Aptose Total Current Liabilities vs Net Debt Analysis

Total Current Liabilities vs Net Debt

Total Current Liabilities vs Net Debt Correlation Analysis

Correlation Coefficient

Total Current Liabilities

Net Debt

Aptose Biosciences fundamental ratios Correlations

Aptose Biosciences Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Aptose Biosciences fundamental ratios Accounts

Pair Trading with Aptose Biosciences

Moving against Aptose Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Total Liab	+ 1.0	Total Current Liabilities
Total Current Assets	+ 1.0	Cash And Short Term Investments
Total Stockholder Equity	+ 0.99	Total Assets
Cash And Short Term Investments	+ 0.99	Total Stockholder Equity

Cash	- 1.0	Net Debt
Common Stock Total Equity	- 0.97	Retained Earnings
Total Current Assets	- 0.96	Net Debt
Cash And Short Term Investments	- 0.96	Net Debt
Net Debt	- 0.96	Total Stockholder Equity
Net Debt	- 0.96	Total Assets